Search fresh public links, source activity, and ready-to-use post angles for Buy-And-Bill.
Fresh curated links around Buy-and-Bill are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
By Tyler Novotny and Bryce Platt PBM-affiliated private label biosimilars would seem to have a built-in formulary advantage. But for ustekinumab, that advantage has not carrie...
By Bryce Platt, PharmD Provider-administered drugs are one of the fastest-growing and least-managed cost drivers for commercial plan sponsors. Despite that, recent data from...
The Trump administration advances a claims-based rebate model for select 340B drugs as a new bipartisan Senate bill would block it, forcing health systems to track three reform pat...
By Greis Kapexhiu and Adam J. Fein, Ph.D. In June 2025, the FDA announced that CAR-T therapies would no longer be subject to a REMS program. The FDA’s removal of CAR-T REMS...
The model offers members potential savings of up to $150,000, executives say.
Hazel Marimbizain Bulawayo BULAWAYO City Council has partnered the National Pharmaceutical Company (NatPharm) to supply essential medicines to 21 municipal clinics, tackling......
By Bryce Platt, PharmD Summer's in full swing, but the drug channel didn't take a break. What better way to spend the summer than reading about new pharmacy resources in the...
The tally reflects a 23% increase over 2024, another substantial escalation in scale for the subsidy program critics say is being abused by large nonprofit hospitals.
A bipartisan group of six senators introduced a bill to reform the 340B drug program, locking in hospitals’ use of contract pharmacies and adding new transparency and compliance ru...
Seventy-six percent expect orchestration to become a funded strategic priority by 2028 as supplier-risk transparency, substitution automation and service accountability move into b...
A notice from the Health Resources & Services Administration sidelines covered entities' attestations of substantial administrative burden and sets the mulligan program into mo...
The true cost of “vertical integration”: patients directed to a higher-priced location for procedures. Or forced to buy from their insurer’s wholly owned pharmacy, which may not st...
Tanvi Patel, vice president and general manager of Amazon Pharmacy, and her co-panelists at the recent Bullseye event, explained why PBMs, payers and doctors are all hampering cons...
The SUSTAIN 340B Act introduced Wednesday would bring hospital-backed changes, like a clearinghouse to handle improper discounts and codify longstanding grey areas in the contentio...
Today's guest post comes from Divya Iyer, SVP, Head of Revenue, Pharma Direct at GoodRx. Divya examines why direct-to-consumer strategies shouldn't default to mail-order as the en...
By Adam J. Fein, Ph.D. and Greis Kapexhiu In late June, the boffins at the Centers for Medicare & Medicaid Services (CMS) released the latest projections for U.S. spending on...
The Bridge program, which began July 1, makes some Medicare beneficiaries eligible for obesity drugs for $50 a month. CVS and Walgreens say they've each already filled 100,000 such...
By Bryce Platt, PharmD Kids are heading back to school, but the drug channel never stops handing out homework. Fortunately, we did some of the research prep for you. In this...
The Health Resources and Services Administration is again pushing to include rebates in the drug discount program after a failed attempt earlier this year. Hospitals railed against...
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.